46 results
8-K
EX-1.1
IMNM
Immunome Inc
14 Feb 24
Other Events
4:11pm
to the Representatives to the extent they are filed on EDGAR.
(m) Record Retention. For a period of three (3) years from the date of this Agreement, the Company
424B5
IMNM
Immunome Inc
14 Feb 24
Prospectus supplement for primary offering
4:09pm
driven by increased tumor uptake and retention.
On January 5, 2024, we entered into an exclusive license with Zentalis Pharmaceuticals, Inc … and retention.
On January 5, 2024, we entered into an exclusive license with Zentalis Pharmaceuticals, Inc., or Zentalis, pursuant to which we received
424B5
gq1i6miyzuzf fi76
13 Feb 24
Prospectus supplement for primary offering
4:36pm
8-K
EX-99.1
79qetmjngkj0nmvo
13 Feb 24
Results of Operations and Financial Condition
4:10pm
S-3ASR
odqqugtm
13 Feb 24
Automatic shelf registration
4:04pm
8-K
EX-2.1
n6zo95x
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
8-K
EX-99.1
vh2pbj36
11 Jan 24
Regulation FD Disclosure
5:27pm
8-K
yf9vqovc3r ojzr
29 Dec 23
Departure of Directors or Certain Officers
5:00pm
8-K
EX-99.1
uz8 51kra73mtg7
15 Nov 23
Regulation FD Disclosure
6:03am
424B3
6ia4fq1gc1q
28 Aug 23
Prospectus supplement
9:10am
S-4/A
pk6uh37mx18zo
25 Aug 23
Registration of securities issued in business combination transactions (amended)
6:38am
S-4
EX-10.49
hjrq74jkavvs0
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm
S-4
aqpp 2zwl4flki5
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm
425
EX-99.1
y336yismbp8 n8e2v
5 Jul 23
Business combination disclosure
5:15pm